ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial- stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market on Wednesday, May 8, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 8, 4:30 PM EDT Domestic: 877-407-8835 International: located here Confere ...

ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market on Wednesday, May 8, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 8, 4:30 PM EDTDomestic: 877-407-8835International: located hereConference ...

ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024. Our first general wellness product, Truvaga 350, exceeded our expectations and Truvaga Plus will be an exciting addition to the Truvaga brand. Truvaga Plus is engineered to seamles ...

electroCore, Inc. (NASDAQ:ECOR) Q4 2023 Earnings Conference Call March 13, 2024 4:30 PM ET Company Participants Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Anthony Vendetti - Maxim Group Operator Hello, and welcome to the electroCore Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow ...

ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $1.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10.91%. A quarter ago, it was expected that this company would post a loss of $0.64 per share when it actually produced a loss of $0.68, delivering a surprise of -6.25%.Over the last four quarters, the company has not b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38538 Washington, D.C. 20549 electroCore, Inc. FORM 10-K (Exact name of Registrant as specified in its Charter) (Mark One) (State or other jurisdiction of incorporation or organization) 200 Forge Way, Suite 205, Rockaway, NJ 07866 (Address of principal executive offices) (Zip Code) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended Decemb ...

ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, March 13, 4:30 PM ESTDomestic: 877-407-8835International: loc ...

ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID). U.S. Patent No. 11,894,148 entitled "Systems and Methods for Treating Patients With Diseases Associated With Viruses" generally relates to methods for treating disorder ...

electroCore, Inc. (NASDAQ:ECOR) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Dan Goldberger – Chief Executive Officer Brian Posner – Chief Financial Officer Conference Call Participants Destiny Hance – Ladenburg Thalmann Ramakanth Swayampakula – H.C. Wainwright Nick Sherwood – Maxim Group, LLC Walter Schenker – MAZ Partners Operator Greetings, and welcome to the electroCore Third Quarter 2023 Earnings Conference Call. At this time, all participants on a listen only mode. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______________ TO ______________ Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its charter) Delaware 20-345497 ...